Du Dan, Liang Yuan
General Practice, 920th Hospital of Joint Logistics Support Force, PLA, Kunming, 650032, China.
J Orthop Surg Res. 2025 Jan 17;20(1):57. doi: 10.1186/s13018-024-05429-w.
KOA, a chronic degenerative joint disease, is commonly treated with intra-articular HA and PRP, used alone or in combination. However, the efficacy and safety of combination therapy (PRP + HA) remain unclear.
The aim of this systematic review and meta-analysis is to assess the clinical effectiveness and safety profile of PRP + HA versus PRP monotherapy for KOA.
A systematic search was conducted using four electronic databases (PubMed, EMBASE, Scopus, and Cochrane Library) to select publications published in peer-reviewed journals. The mean difference (MD) and risk ratio (RR) was calculated, along with their 95% confidence intervals. We assessed heterogeneity using Cochrane Q and Istatistics and the appropriate p-value. The analysis used RevMan 5.4. GRADE system was used for evidence assessment for each outcome parameter.
This meta-analysis of 11 RCTs (n = 1023 KOA patients) revealed that PRP + HA has substantial effectiveness than PRP alone in reducing OMAC total scores [MD -1.77 (95% CI -2.20 to - 1.34); I2 = 10%, and p < 0.001], VAS scores [MD -4.27 (95% CI -4.96 to - 3.58); I = 13%, and p < 0.001], and Lequesne index score [MD -5.48 (95% CI -6.56 to - 4.40); I = 16%, and p < 0.001], while increasing IKDC scores [MD -2.10 (95% CI -3.70 to - 0.50); I = 9%, and p = 0.01], with low risk of adverse events [RR 0.41 (95% CI 0.35 to 0.48); I = 12%, and p < 0.001].
This meta-analysis reveals that, for patients with KOA, PRP + HA therapy is safe and yields better outcomes in pain relief and functional improvement compared to PRP monotherapy.
膝骨关节炎(KOA)是一种慢性退行性关节疾病,常用关节腔内注射透明质酸(HA)和富血小板血浆(PRP)进行治疗,可单独使用或联合使用。然而,联合治疗(PRP + HA)的疗效和安全性仍不明确。
本系统评价和荟萃分析的目的是评估PRP + HA与PRP单药治疗KOA的临床有效性和安全性。
使用四个电子数据库(PubMed、EMBASE、Scopus和Cochrane图书馆)进行系统检索,以选择在同行评审期刊上发表的文献。计算平均差(MD)和风险比(RR)及其95%置信区间。我们使用Cochrane Q和I统计量以及适当的p值评估异质性。分析使用RevMan 5.4。采用GRADE系统对每个结局参数进行证据评估。
对11项随机对照试验(n = 1023例KOA患者)的荟萃分析显示,与单独使用PRP相比,PRP + HA在降低西安大略和麦克马斯特大学骨关节炎指数(OMAC)总分[MD -1.77(95%CI -2.20至-1.34);I² = 10%,p < 0.001]、视觉模拟评分(VAS)[MD -4.27(95%CI -4.96至-3.58);I² = 13%,p < 0.001]和勒奎斯恩指数评分[MD -5.48(95%CI -6.56至-4.40);I² = 16%,p < 0.001]方面具有显著疗效,同时增加国际膝关节文献委员会(IKDC)评分[MD -2.10(95%CI -3.70至-0.50);I² = 9%,p = 0.01],不良事件风险较低[RR 0.41(95%CI 0.35至0.48);I² = 12%,p < 0.001]。
本荟萃分析表明,对于KOA患者,PRP + HA治疗是安全的,与PRP单药治疗相比,在缓解疼痛和改善功能方面能产生更好的效果。